WO2002066982A8 - Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) - Google Patents

Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)

Info

Publication number
WO2002066982A8
WO2002066982A8 PCT/EP2002/001781 EP0201781W WO02066982A8 WO 2002066982 A8 WO2002066982 A8 WO 2002066982A8 EP 0201781 W EP0201781 W EP 0201781W WO 02066982 A8 WO02066982 A8 WO 02066982A8
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
ubiquitin
demodification
modification
related proteins
Prior art date
Application number
PCT/EP2002/001781
Other languages
English (en)
French (fr)
Other versions
WO2002066982A1 (de
WO2002066982A2 (de
WO2002066982A3 (de
Inventor
Frauke Melchior
Ulrike Gaertner
Tanja Buesgen
Marion Schergaut
Sowmya Swaminathan
Original Assignee
Max Planck Gesellschaft
Frauke Melchior
Ulrike Gaertner
Tanja Buesgen
Gast Andreas
Pichler Andrea
Marion Schergaut
Sowmya Swaminathan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Frauke Melchior, Ulrike Gaertner, Tanja Buesgen, Gast Andreas, Pichler Andrea, Marion Schergaut, Sowmya Swaminathan filed Critical Max Planck Gesellschaft
Publication of WO2002066982A1 publication Critical patent/WO2002066982A1/de
Publication of WO2002066982A2 publication Critical patent/WO2002066982A2/de
Publication of WO2002066982A8 publication Critical patent/WO2002066982A8/de
Publication of WO2002066982A3 publication Critical patent/WO2002066982A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft Verfahren zur Analyse von Modifizierungen von Proteinen mit Ubiquitin-verwandten Proteinen und von Demodifizierungen von Proteinen, die mit Ubiquitin-verwandten Proteinen verknüpft sind. Desweiteren betrifft die Erfindung Verfahren zum Bestimmen von Stoffen, die diese Modifizierungen bzw. Demodifizierungen beeinflussen, sowie Verfahren zum Nachweis eines Defekts in diesen Modifizierungen bzw. Demodifizierungen. Schließlich betrifft die Erfindung ein Verfahren zur Identifizierung von Zielproteinen für die Modifizierung mit Ubiquitin-verwandten Proteinen als auch Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung. Darüber hinaus betrifft die Erfindung einen Kit, ein Fusionsprotein, eine Zelle und ein Isopeptidase-Substrat und deren Verwendungen in der Analytik und/oder Diagnostik von Ubiquitin-verwandten Modifizierung bzw. Demodifizierungen von Protein.
PCT/EP2002/001781 2001-02-21 2002-02-20 Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) WO2002066982A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108263.0 2001-02-21
DE2001108263 DE10108263A1 (de) 2001-02-21 2001-02-21 Analyse von Modifizierungen und Demodifizierungen von Proteinen mit Ubiquitinverwandten Proteinen mittels FRET (Fluorescence Resonance Energy Transfer)

Publications (4)

Publication Number Publication Date
WO2002066982A1 WO2002066982A1 (de) 2002-08-29
WO2002066982A2 WO2002066982A2 (de) 2002-08-29
WO2002066982A8 true WO2002066982A8 (de) 2002-10-31
WO2002066982A3 WO2002066982A3 (de) 2002-12-27

Family

ID=

Also Published As

Publication number Publication date
WO2002066982A1 (de) 2002-08-29
DE10108263A1 (de) 2002-09-05
WO2002066982A3 (de) 2002-12-27

Similar Documents

Publication Publication Date Title
EP1348713A3 (de) Markierungsstoffe und Markierungsprozesse zur Bestimmung von Nukleinsäuren
WO2002079490A3 (en) Bio-barcodes based on oligonucleotide-modified particles
WO2004055519A3 (en) Specific markers for pancreatic cancer
EP2266996A3 (de) Markierungsstrategie für die empfindliche Detektion von Analyten
WO2001042502A3 (en) Methods for disease detection
WO2005050224A3 (en) Small molecule and peptide arrays and uses thereof
WO2006078289A3 (en) Bio-barcode based detection of target analytes
EP2287618A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
DE602007011937D1 (de) Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
WO2008151207A3 (en) Expression quantification using mass spectrometry
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
AU2003260457A1 (en) A method and kit for the quantitative and/or qualitative detection of components in a sample
WO2021021964A3 (en) Methods of quantifying frataxin and frataxin fusion proteins
WO2005019831A3 (en) Methods for reducing complexity of a sample using small epitope antibodies
EP1560025A3 (de) Marker spezifisch für Diabetes
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
WO2006004936A3 (en) Analysis of intracellular modifications
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
WO2004113574A3 (en) Methods for disease screening
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2002 REPLACE "A1" BY "A2" AND UNDER "PUBLISHED", REPLACE "WITH INTERNATIONAL SEARCH REPORT" BY "WITHOUT INTERNATIONAL SEARCH REPORT"

Free format text: PAT. BUL. 35/2002 REPLACE "A1" BY "A2" AND UNDER "PUBLISHED", REPLACE "WITH INTERNATIONAL SEARCH REPORT" BY "WITHOUT INTERNATIONAL SEARCH REPORT"

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP